Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are bacterial infections in which a large abnormal region of tissue is formed near wounds

 

Acute Bacterial Skin and Skin Structure Infections

Acute bacterial skin and skin structure infections (ABSSSI) are common, especially among children. The reason for this is that children's bladders do not fully develop until the age of two, making it easier for bacteria to travel up into the lungs and the mouth. In addition, certain drugs such as some antibiotics can cause acute bacterial infections as well.

One of the most common drugs used for treating such infections is Fluconazole (FLZ), which is administered orally on a daily basis in most cases. For children who suffer from acute bacterial skin and skin structure infections (ABSSSI), the U.S. Food and Drug Administration (FDA) has approved the use of fluconazole (FLZ) in combination with other drugs to effectively treat the infection.

Children who suffer from this condition should be administered at least one course of a combination treatment containing either amikacin or econazole, at least seven days apart. If the infection does not respond adequately in this amount of time, additional courses may be needed. Some of these side effects include vomiting, nausea, and abdominal pain.

Children with complicated skin structure infections often have difficulty maintaining appropriate fluid and electrolyte balance. This can lead to complications, such as vomiting, dehydration, electrolyte imbalances, fever, and shock. Considering these complications, antibiotics are not usually administered for this condition. On the other hand, a large percentage of patients with acute bacterial skin structure infections respond to antibiotics. For instance, in March 2021, the U.S. Food and Drug Administration (FDA) granted approval for KIMYRSA (Melinta Therapeutics) for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.

As an alternative to antibiotics, acid reducers are often used in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Acid reducers inhibit the synthesis of all known types of bacteria, including Escherichia coli, Staphylococcus aureus, and yeast. Limited clinical studies demonstrate that acid reducers improve both the quality and duration of antibiotic therapy for bacterial skin infections caused by Pseudomonas species. For most types of acute bacterial skin and skin structure infections (ABSSSI), patients will be given a single dose of the acid reducer, which can be administered up to four times daily.


Comments

Popular posts from this blog

Light Linear Alpha Olefins Are Produces through Oligomerization of Ethylene and by Fischer-Tropsch Synthesis

Cervical Cancer Diagnostic Tests have become highly sophisticated with accurate diagnosis for effective treatment

Commercial laundry equipment are key attributes for cleaning and laundry industries